Literature DB >> 12209539

Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis.

Peter D Kent, John M Davis, Mark D P Davis, Eric L Matteson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12209539     DOI： 10.1002/art.10348

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  3 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

3.  The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes.

Authors:  Sarah Elliott; Ezra Hays; Michael Mayor; Michael Sporn; Matthew Vincenti
Journal:  Arthritis Res Ther       Date:  2003-07-08       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.